ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).
30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video
30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video
ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).